Insider Selling: Exelixis (NASDAQ:EXEL) Director Sells 3,856 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Sue Gail Eckhardt sold 3,856 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $43.79, for a total value of $168,854.24. Following the completion of the transaction, the director owned 17,524 shares in the company, valued at approximately $767,375.96. The trade was a 18.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Exelixis Stock Performance

Exelixis stock traded up $0.39 during mid-day trading on Wednesday, reaching $44.47. The stock had a trading volume of 3,267,412 shares, compared to its average volume of 2,563,792. The firm has a market capitalization of $11.55 billion, a PE ratio of 16.05, a price-to-earnings-growth ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62. The stock’s 50-day simple moving average is $43.77 and its 200-day simple moving average is $41.13.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. During the same period in the prior year, the firm earned $0.55 earnings per share. Exelixis’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Guggenheim cut shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. Royal Bank Of Canada raised their price target on shares of Exelixis from $45.00 to $46.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 11th. Morgan Stanley lifted their price target on Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Wall Street Zen downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $47.11.

Hedge Funds Weigh In On Exelixis

Several institutional investors have recently modified their holdings of EXEL. Richardson Financial Services Inc. increased its position in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares during the last quarter. Anchor Investment Management LLC boosted its position in Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares during the last quarter. Motiv8 Investments LLC bought a new position in Exelixis in the 4th quarter valued at $26,000. Root Financial Partners LLC purchased a new stake in shares of Exelixis during the 3rd quarter valued at $28,000. Finally, Acumen Wealth Advisors LLC bought a new stake in shares of Exelixis during the 4th quarter worth $29,000. 85.27% of the stock is owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.